The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients [14]

Leukemia

Volumn 19, Issue 12, 2005, Pages 2359-2360

  Ohyashiki, K ^a   Aota, Y ^a   Akahane, D ^a   Gotoh, A ^a   Miyazawa, K ^a   Kimura, Y ^a   Ohyashiki, J H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; FLUORESCENCE CORRELATION SPECTROSCOPY; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; LETTER; LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 28544431813     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403989     Document Type: Letter

References (7)

1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of Jak2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell 2005; 7: 387-397.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 484: 1144-1148.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferaive disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
6. Ohyashiki K, Sasao I, Ohyashiki JH, Murakami T, Iwabuchi A, Tauchi T et al. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 1991; 68: 178-183.
7. Ohyashiki K, Yokoyama K, Kimura Y, Ohyashiki JH, Ito Y, Kuratsuji T et al. Myelodysplastic syndrome evolving into a myeloproliferative disorder: One disease or two? Leukemia 1993; 7: 338-340.